BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Triposkiadis F, Xanthopoulos A, Bargiota A, Kitai T, Katsiki N, Farmakis D, Skoularigis J, Starling RC, Iliodromitis E. Diabetes Mellitus and Heart Failure. J Clin Med 2021;10:3682. [PMID: 34441977 DOI: 10.3390/jcm10163682] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhao X, Liu S, Wang X, Chen Y, Pang P, Yang Q, Lin J, Deng S, Wu S, Fan G, Wang B. Diabetic cardiomyopathy: Clinical phenotype and practice. Front Endocrinol (Lausanne) 2022;13:1032268. [PMID: 36568097 DOI: 10.3389/fendo.2022.1032268] [Reference Citation Analysis]
2 Demarsilis A, Reddy N, Boutari C, Filippaios A, Sternthal E, Katsiki N, Mantzoros C. Pharmacotherapy of type 2 diabetes: An update and future directions. Metabolism 2022;137:155332. [DOI: 10.1016/j.metabol.2022.155332] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Katsiki N, Kazakos K, Triposkiadis F. Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes. Expert Opinion on Pharmacotherapy 2022. [DOI: 10.1080/14656566.2022.2143263] [Reference Citation Analysis]
4 Sapian S, Taib IS, Katas H, Latip J, Zainalabidin S, Hamid ZA, Anuar NNM, Budin SB. The Role of Anthocyanin in Modulating Diabetic Cardiovascular Disease and Its Potential to Be Developed as a Nutraceutical. Pharmaceuticals 2022;15:1344. [DOI: 10.3390/ph15111344] [Reference Citation Analysis]
5 Katsiadas N, Xanthopoulos A, Giamouzis G, Skoularigkis S, Skopeliti N, Moustaferi E, Ioannidis I, Patsilinakos S, Triposkiadis F, Skoularigis J. The effect of SGLT-2i administration on red blood cell distribution width in patients with heart failure and type 2 diabetes mellitus: A randomized study. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.984092] [Reference Citation Analysis]
6 Bourazana A, Giamouzis G, Skoularigis J, Triposkiadis F, Xanthopoulos A. Glucose lowering does not necessarily reduce cardiovascular risk in type 2 diabetes. World J Cardiol 2022; 14(4): 266-270 [DOI: 10.4330/wjc.v14.i4.266] [Reference Citation Analysis]
7 Simou A, Xanthopoulos A, Giamouzis G, Papagiannis D, Dimos A, Economou D, Skoularigis J, Triposkiadis F. Coexisting morbidity burden in elderly hospitalized patients with and without heart failure. Hellenic Journal of Cardiology 2022. [DOI: 10.1016/j.hjc.2022.02.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zhao Y, Sun Q, Xu Z, Li M, Tian G, Khalaf OI. Effect of Ghrelin Intervention on the Ras/ERK Pathway in the Regulation of Heart Failure by PTEN. Computational and Mathematical Methods in Medicine 2022;2022:1-10. [DOI: 10.1155/2022/1045681] [Reference Citation Analysis]
9 Boschetti D, Muller CR, Américo ALV, Vecchiatto B, Martucci LF, Pereira RO, Oliveira CP, Fiorino P, Evangelista FS, Azevedo-Martins AK. Aerobic Physical Exercise Improves Exercise Tolerance and Fasting Glycemia Independent of Body Weight Change in Obese Females. Front Endocrinol (Lausanne) 2021;12:772914. [PMID: 34970223 DOI: 10.3389/fendo.2021.772914] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL, Tasto C, Joseph A, Kolkhof P, Lage A, Pitt B; FIGARO-DKD Investigators. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses from the FIGARO-DKD Trial. Circulation 2021. [PMID: 34775784 DOI: 10.1161/CIRCULATIONAHA.121.057983] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 12.0] [Reference Citation Analysis]